Pricey rare disease drug’s launch will be likely focus of Biogen earnings
April 24, 2017 at 10:27 AM EDT
Spinraza’s price tag — up to $750,000 in the first year — has attracted criticism.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.